IDEC/GENENTECH RITUXAN NON-HODGKIN'S LYMPHOMA RESPONDERS: HALF IN REMISSION AT ONE YEAR; FIRST-LINE AND COMBINATION CHEMOTHERAPY STUDIES WITH MAB PLANNED
Half of the responders to Idec/Genentech's Rituxan for non-Hodgkin's lymphoma remain in remission, Idec said July 25 following a favorable review by FDA's Biological Response Modifiers Advisory Committee. Of 80 responders in the Rituxan pivotal trial, 38 are still in remission 11.8 months following treatment.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth